RSV Seasonal Vaccine Introduction and Growth Strategy
Arexvy approved ahead of 2023/24 RSV season
Adults aged 60 and older can be protected from RSV disease for the first time
Exceptional efficacy for
patients aged 60 years or older
Efficacy against RSV LRTD in patients
with at least one comorbidity
94.6%
Overall efficacy against RSV-LRTD
82.6%
US CDC recommends Arexvy
for upcoming RSV season²
.
•
Recommended for adults aged 60
and older with shared clinical
decision making²
77 million older adults in the US¹
could be eligible for RSV vaccination
for the first time
CDC recommends vaccination as
early as vaccines become available²
Launch preparations
progressing as planned
• Vaccine and respiratory franchise
expertise will lead to significant
retailer and HCP reach
US: doses shipped to distribution
centers; Disease awareness
campaign launched
• EU: launching in Q3 2023
Adults aged 60+ at risk of annual
exposure to RSV
>lbn
GSK
1.2021 US Census: adults age 60 and older
2. Morbidity and Mortality Weekly Report, accessed 20 July 2023: https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7229a4-H.pdf
17View entire presentation